2025
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer
Herbst R, John T, Grohé C, Goldman J, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Dómine M, Ahn M, Kowalski D, Pérol M, Sriuranpong V, Özgüroğlu M, Bhetariya P, Markovets A, Rukazenkov Y, Muldoon C, Robichaux J, Hartmaier R, Tsuboi M, Wu Y. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer. Nature Medicine 2025, 31: 1958-1968. PMID: 40097663, PMCID: PMC12176615, DOI: 10.1038/s41591-025-03577-y.Peer-Reviewed Original ResearchConceptsMolecular residual diseaseDisease-free survivalNon-small-cell lung cancerDisease-free survival eventsEvent-free rateAdjuvant osimertinibOsimertinib treatmentStage IB-IIIA non-small-cell lung cancerLung cancerOverall survival improvementEvent-free statusPosttreatment Follow-upExploratory post hoc analysisYear adjuvant treatmentPost Hoc AnalysisDFS eventsOsimertinib groupResidual diseaseTreatment discontinuationPlacebo groupAdjuvant therapyAdjuvant treatmentSurvival improvementOsimertinibFollow-up
2018
Complete metabolic response to therapy of hepatic epithelioid hemangioendothelioma evaluated with 18F-fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography
Giancipoli R, Monti S, Basturk O, Klimstra D, Keohan M, Schillaci O, Corrias G, Sawan P, Mannelli L. Complete metabolic response to therapy of hepatic epithelioid hemangioendothelioma evaluated with 18F-fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography. Medicine 2018, 97: e12795. PMID: 30334971, PMCID: PMC6211838, DOI: 10.1097/md.0000000000012795.Peer-Reviewed Original ResearchConceptsF-FDG PET/CTDiagnosis of epithelioid hemangioendotheliomaMetabolic response to therapyHepatic epithelioid hemangioendotheliomaF-FDGVascular endothelial growth factorEpithelioid hemangioendotheliomaResponse to therapyAnti-angiogenic agentsF-FDG PET-CT scanInhibitor of vascular endothelial growth factorRare malignant vascular tumorPET-CT scanFollow-up CTMalignant vascular tumorsVariable clinical presentationRight upper quadrantLymph node lesionsMultiple hepatic massesPosttreatment Follow-upEndothelial growth factorFDG avidityCyclophosphamide treatmentF-fluorodeoxyglucoseClinical presentation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply